Humanized anti-sialyl-tn glycan antibodies and uses thereof
AssigneeRamot at Tel-Aviv University Ltd.
InventorsVered PADLER-KARAVANI, Ron AMON
Life of this patent
Estimating the term…
Abstract
The present invention discloses humanized monoclonal antibodies that specifically bind to STn carbohydrate antigen with high specificity and selectivity, functional fragments of the humanized monoclonal antibodies such as scFv, conjugates and chimeric antigen receptors comprising the humanized monoclonal antibodies or the fragment thereof such as scFv. The invention further provides cells and compositions comprising the antibodies, fragments thereof or CARs as well as their use in diagnostics and treatment of cancer.
Claims21
1-52. (canceled)
A humanized monoclonal antibody (mAb) or a fragment thereof that specifically binds to Sialyl Tn (STn) glycan, comprising an antigen-binding domain comprising a heavy-chain variable domain (VH) and a light-chain variable domain (VL), wherein the VH and the VL each comprises three complementarity determining regions (CDRs) and four framework regions (FR), wherein the VH domain comprises amino acid sequence SEQ ID NO:1 in which from 9 to 16 amino acids in the framework regions are substituted and the VL domain comprises amino acid sequence SEQ ID NO:2 in which from 9 to 20 amino acids in the framework regions are substituted.
The humanized mAb or the fragment according to 53, characterized by one of:
- (i) said antibody or fragment binds STn glycan with an equilibrium dissociation constant (KD) of from about 0.01 to about 30 nM or from 0.02 to 0.5 nM;
- (ii) wherein the fragment is a single chain variable fragment (scFv);
- (iii) wherein the fragment is a single chain variable fragment (scFv) comprising an amino acid sequence selected from SEQ ID NO:
- 31 and 32.
Dependencies are inferred from the claim text.